Organon Involved in Unique Initiative for the Development and Production of Biopharmaceutical Medicines

01-Mar-2005

BioConnection - a collaboration involving Akzo Nobel's human healthcare business, government authorities in the Netherlands and the Dutch business community - will be the first "one-stop shop" in Europe to offer start-up biopharmaceutical companies the use of dedicated and centralized production facilities.

The BioConnection biotechnology center will be based at Organon's Oss site in the Netherlands, where part of the company's facilities will be made available. These resources are intended for use by small and medium-sized biopharmaceutical businesses that do not have their own production facilities.

Set up with a total investment of EUR 15 million, BioConnection intends to provide young biopharmaceutical companies with access to a network of service and knowledge providers-including Organon - who will pass on their expertise in the area of development and production, both for active biopharmaceutical ingredients and biopharmaceutical end products.

The lack of such facilities has, until now, proved to be a serious hindrance to the continued development of the biopharmaceutical sector and the emergence of new drugs.

Having been granted user rights to the Organon facilities, start-up biopharmaceutical companies will have access to an ultramodern installation which meets all safety and production requirements for the manufacture of medicines, from small-scale tests right up to large-scale commercial production.

The Dutch government is keen to foster the growth of the life sciences industry in the Netherlands and the BioConnection initiative is seen as being the ideal way to stimulate the growth of young, small-scale companies by using market-driven investments in high-quality production facilities and knowledge networks.

https://www.bionity.com/en/news/43832/organon-involved-in-unique-initiative-for-the-development-and-production-of-biopharmaceutical-medicines.html